Stockholders’ Equity (Details Narrative) - USD ($)																																		1 Months Ended		3 Months Ended						9 Months Ended
	Sep. 16, 2024	Jul. 05, 2024	Jun. 30, 2024	Jun. 28, 2024	Jun. 21, 2024	Jun. 14, 2024	Jun. 07, 2024	May 31, 2024	May 24, 2024	May 17, 2024	May 10, 2024	May 01, 2024	Apr. 16, 2024	Apr. 15, 2024	Apr. 05, 2024	Mar. 27, 2024	Feb. 16, 2024	Feb. 02, 2024	Jan. 31, 2024	Jan. 19, 2024	Jan. 04, 2024	Dec. 29, 2023	Dec. 27, 2023	Nov. 20, 2023	Nov. 19, 2023	Aug. 10, 2023	Aug. 08, 2023	Aug. 04, 2023	Jul. 26, 2023	Jul. 07, 2023	Mar. 27, 2023	Mar. 23, 2023	Feb. 03, 2023	Apr. 30, 2024	Aug. 31, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Apr. 17, 2024	Dec. 31, 2023	Oct. 22, 2023	Oct. 13, 2023	Oct. 12, 2023	Jun. 28, 2023	Jun. 27, 2023
Common stock, shares authorized																																				50,000,000						50,000,000			50,000,000		50,000,000	6,250,000
Gross proceeds																																					$ 165,131		$ 2,996,061	$ 20,297	$ 2,708,642
Number of shares issued private offering value																																										$ 1,643,904
Exercise price																																												$ 1.20
Additional gross proceeds from warrants exercises																																										900,611
Proceeds from sale of common stock																																										$ 165,131	$ 5,725,000
Common stock, par value																																				$ 0.0001						$ 0.0001			$ 0.0001
Stock issued during for services, value																																				$ 37,295	$ 59,998	$ 142,450	$ 11,249	$ 94,276	149,900
Exercise warrants to purchase shares
Exercised warrants issued, value																																									$ 2,376
Common Stock [Member]
Warrants to purchase shares																																					260,000		1,587,500	115,000	69,000
Gross proceeds																																					$ 26		$ 158	$ 12	$ 7
Purchase warrants exercisable																																					807,000		43,985
Stock issued during for services																																				42,000	69,155	125,500		12,817	13,000
Stock issued during for services, value																																				$ 5	$ 6	$ 13		$ 2	$ 1
Exercise warrants to purchase shares																																									297
Exercised warrants issued, value
Public Offering [Member]
Share price																											$ 2.85
February Investors [Member]
Warrants to purchase shares																																	7,500
February Debentures [Member]
Repayments of debt																											$ 139,849
Fee amount																											10,911
NAYA Biosciences Merger [Member]
Preferred stock, par value																							$ 5.00																							$ 5.00
Common stock, par value																																														$ 0.0001
Purchase agreement, description																							The parties further agreed to the following schedule (the “Minimum Interim Pipe Schedule”) for the initial $2,000,000: (1) $500,000 no later than December 29, 2023, (2) $500,000 no later than January 19, 2024, (3) $500,000 no later than February 2, 2024, and (4) $500,000 no later than February 16, 2024.
Securities Purchase Agreement [Member]
Warrants to purchase shares	27,500		140,080											61,200					100,000
Shares issued price per share																																$ 12.60
Gross proceeds	$ 137,500		$ 700,404											$ 306,000					$ 500,000
Number of warrants issued																																115,000
Exercise price																														$ 2.85		$ 0.20
Purchase warrants exercisable																																276,000
Amendment fee																														$ 1,000,000
Stock issued during for services																																69,000
Securities Purchase Agreement [Member] | Public Offering [Member]
Warrants to purchase shares																												1,580,000
Number of warrants issued																												3,160,000
Exercise price																												$ 2.85
Sale of stock																												1,580,000
Share price																												$ 2.85
Securities Purchase Agreement [Member] | NAYA Biosciences Merger [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		30,000		30,000	30,000	30,000	30,000	30,000	30,000	30,000	20,000																															598,800
Share Exchange Agreement [Member]
Warrants to purchase shares																									1,200,000
Equity Purchase Agreement [Member]
Proceeds from sale of shares																																	$ 10,000,000.0
Purchase of shares of common stock description																																	(i) in a minimum amount of not less than $25,000 and (ii) in a maximum amount of up to the lesser of (a) $750,000 or (b) 200% of the Company’s average daily trading value of the common stock.
March Purchase Agreement [Member]
Warrants to purchase shares																																69,000
Shares issued price per share																																$ 12.60
Number of warrants issued																																115,000
Exercise price																																$ 0.20
Purchase warrants exercisable																																276,000
Proceeds from issuance initial public offering																															$ 3,000,000
Additional gross proceeds from warrants exercises																															$ 3,500,000
February Debentures [Member]
Proceeds from issuance of debt																																	$ 383,879
Purchase Agreements [Member] | Public Offering [Member]
Warrants to purchase shares																												1,580,000
Number of warrants issued																												3,160,000
Exercise price																												$ 2.85
Sale of stock																												1,580,000
Share price																												$ 2.85
Proceeds from sale of common stock																												$ 4,500,000
Proceeds from issuance or sale of equity																											2,150,000
Purchase price																										$ 350,000
Amendment fee																											$ 1,000,000
Placement Agency Agreement [Member] | Maxim Group LLC [Member]
Exercise price																												$ 3.14
Percentage of pay placement agent aggregate fee																												7.00%
Percentage of investors																												5.00%
Number of warrant purchase, shares																												110,600
Securities Purchase Agreements [Member]
Shares issued price per share																																			$ 2.85
Armistice fee																																			$ 1,000,000
Triton Purchase Agreement [Member]
Warrants to purchase shares															75,000																			260,000
Shares issued price per share																$ 0.85
Gross proceeds																$ 850,000
Proceeds from sale of common stock															$ 10,131																			$ 165,131
Common stock, par value																$ 0.0001
Purchase agreement, description																The Triton Purchase Agreement expires upon the earlier of the sale of all 1,000,000 shares of the Company’s common stock or December 31, 2024.
Proceeds from sale of common stock																260,000
Stock return, shares															185,000
Conversion of period shares																																		109,886
Conversion of period value																																		$ 197,033
Triton Purchase Agreement [Member] | Common Stock [Member]
Proceeds from sale of common stock													$ 155,000
Proceeds from sale of common stock													185,000
Triton Purchase Agreement [Member] | August 2023 Warrants [Member]
Exercise warrants to purchase shares																																		807,000
Exercised warrants issued, value																																		$ 971,012
Triton Purchase Agreement [Member] | Maximum [Member]
Warrants to purchase shares																1,000,000
Series A Preferred Stock [Member]
Warrants to purchase shares																								1,000,000
Shares issued price per share																								$ 5.00
Preferred stock, par value																								5.00												$ 5.00						$ 5.00			5.00
Preferred stock fixed conversion price																								$ 2.20
Preferred stock conversion descripition																								The Company may not effect the conversion of any shares of Series A Preferred if, after giving effect to the conversion or issuance, the holder, together with its affiliates, would beneficially own more than 9.99% of the Company’s outstanding common stock. Moreover, the Company may not effect the conversion of any shares of Series A Preferred if, after giving effect to the conversion or issuance, the holder, together with its affiliates, would beneficially own more than 19.99% of the Company’s outstanding common stock unless and until the Company receives the approval required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or any subsequent trading market).
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member]
Warrants to purchase shares																					100,000	1,000,000														27,500	201,280
Shares issued price per share																						$ 5.00
Number of shares issued private offering value																					$ 500,000															$ 137,500	$ 1,006,400
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | NAYA Biosciences Merger [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares												838,800
Purchase price per share												$ 5.00
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Gross proceeds																						$ 500,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Gross proceeds																				$ 500,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Gross proceeds																		$ 500,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share Based Compensation Award Tranche Four [Member]
Gross proceeds																	$ 500,000
Series B Preferred Stock [Member]
Preferred stock, par value																																				$ 5.00						$ 5.00			$ 5.00
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member]
Warrants to purchase shares																								1,200,000
Shares issued price per share																								$ 5.00
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member] | Nonconsolidated Investees, Other [Member]
Beneficially percentage																								19.99%
Series B Preferred Stock [Member] | Share Exchange Agreement [Member]
Warrants to purchase shares																									163,637
Series B Preferred Stock [Member] | Share Exchange Agreement [Member] | Nonconsolidated Investees, Other [Member]
Beneficially percentage																								6.50%
Board of Directors [Member]
Common stock, shares authorized																																																	6,250,000	125,000,000
Reverse stock split																													the Company filed a certificate of change (with an effective date of July 28, 2023) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 1-for-20 reverse stock split of its outstanding common stock.
Consultant [Member]
Stock issued during for services																																										236,655
Stock issued during for services, value																																										$ 239,743